Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers (2008)

  • Authors:
  • USP affiliated authors: ROCHA, ADRIANA - FCFRP ; COELHO, EDUARDO BARBOSA - FMRP ; LANCHOTE, VERA LUCIA - FCFRP
  • USP Schools: FCFRP; FMRP; FCFRP
  • DOI: 10.1007/s00228-008-0510-x
  • Subjects: GASTROENTEROLOGIA; FARMACOLOGIA
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/s00228-008-0510-x (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: European Journal of Clinical Pharmacology

    ISSN: 0031-6970

    Citescore - 2017: 2.69

    SJR - 2017: 1.159

    SNIP - 2017: 1.277


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FMRP11200052815-Spcd 1689673
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      ROCHA, Adriana; COELHO, Eduardo Barbosa; MOUSSA, Soraia A. P.; LANCHOTE, Vera Lúcia. Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. European Journal of Clinical Pharmacology, Berlin, v. 64, n. 9, p. 901-906, 2008. DOI: 10.1007/s00228-008-0510-x.
    • APA

      Rocha, A., Coelho, E. B., Moussa, S. A. P., & Lanchote, V. L. (2008). Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. European Journal of Clinical Pharmacology, 64( 9), 901-906. doi:10.1007/s00228-008-0510-x
    • NLM

      Rocha A, Coelho EB, Moussa SAP, Lanchote VL. Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. European Journal of Clinical Pharmacology. 2008 ; 64( 9): 901-906.
    • Vancouver

      Rocha A, Coelho EB, Moussa SAP, Lanchote VL. Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. European Journal of Clinical Pharmacology. 2008 ; 64( 9): 901-906.

    Referências citadas na obra
    Ingelman-Sundberg M, Rodriguez-Antona C (2005) Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Phil Trans R Soc B 360:1563–1570
    Brosen K, Naranjo CA (2001) Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 11:275–283
    Ingelman-Sundberg M, Orcarson M, Mclellan RA (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Tips 20:342–349
    Hasler JA, Estabrook R, Murray M, Pikuleva I, Waterman M, Capdevila J, Holla V, Helvig C, Falck JR, Farrel G, Kaminsky LS, Spirovack SD, Boitier E, Beaune P (1999) Human cytochromes P450. Mol Aspects Med 20:1–137
    Rossini A, Soares-Lima S, Rapozo DCM, Faria M, Albano RM, Ribeiro Pinto LF (2006) CYP2A6 and CYP2E1 polymorphisms in a Brazilian population living in Rio de Janeiro. Braz J Med Biol Res 39:195–201
    Suarez-Kurtz G (2005) Pharmacogenomics in admixed populations. Trends Pharmacol Sci 26:196–201
    Carvalho-Silva D, Santos FR, Rocha J, Pena SDJ (2001) The phylogeography of Brazilian Y-chromosome lineages. Am J Hum Genet 68:281–286
    Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45:13–31
    Rogers JF, Rocci ML, Haughey DB, Bertino JS (2003) An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytocrome P4503A activity. Clin Pharmacol Therap 73:153–158
    Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y, Kobayashi S, Thummel KE, Wilkinson GR (2001) CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 69:333–339
    Kim M-J, Nafziger AN, Zhang Y, Sellers EM, Gaedigk A, Bertino JS Jr (2004) Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping. J Clin Pharmacol 44:966–973
    Rosemary J, Adithan C, Padmaja N, Shashindran CH, Gerard N, Krishnamoorthy R (2005) The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in south Indians. Eur J Clin Pharmacol 61:19–23
    Marinac JS, Balian J, Foxworth JW, Willsie SK, Daus JC, Owen R, Flockhart DA (1996) Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 60:138–144
    Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83:322–327
    Sim SC, Risinger C, Dahl M-L, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113
    González HM, Romero EM, Chavez TJ, Peregrina AA, Chávez TJ, Escobar-Islas E, Lozano F, Hoyo-Vadillo C (2003) CYP2C19 and CYP3A4-dependent omeprazole metabolism in west Mexicans. J Clin Pharmacol 43:1211–1215
    González HM, Romero EM, Chavez TJ, Peregrina AA, Quezada V, Hoyo-Vadillo C (2002) Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction. J Chromatogr B 780:459–465
    Kanazawa H, Okada A, Higaki M, Yokota H, Mashige F, Nakahara K (2003) Stereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype. J Pharm Biomed Anal 30:1817–1824
    Yin OQP, Tomlinson B, Chow AHL, Waye MM, Chow MSS (2004) Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. J Clin Pharmacol 44:582–589
    Bottiger Y (2006) Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. Eur J Clin Pharmacol 62:621–625
    Goldstein JA, Blaisdell J (1996) Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 272:210–218
    Jabor VAP, Coelho EB, Santos NAG, Bonato PS, Lanchote VL (2005) A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism. J Chromatogr B 822:27–32
    Schellens JHM, Van Der Wart JHF, Danhof M, Van Der Velde EA (1988) Relationship between the metabolism of antipyrine, hexobarbitone and theophyline in man as assessed by a cocktail approach. Br J Clin Pharmacol 26:373–384
    Chang M, Tybring G, Dahl M-L, Gotharson E, Sagar M, Seensalu R, Bertilsson L (1995) Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39:511–518
    Yu B-N, Chen G-L, He N, Ouyang D-S, Chen X-P, Liu Z-Q, Zhou H-H (2003) Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metabol Dispos 31:1255–1259
    Yang YS, Wong LP, Lee TC, Mustafa AM, Mohamed Z, Lang CC (2004) Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol 58:332–335
    Lamba JK, Lin YS, Schuetz ER, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv 54:1271–1294